| Biologically informed deep neural network for prostate cancer discovery HA Elmarakeby, J Hwang, R Arafeh, J Crowdis, S Gang, D Liu, ... Nature 598 (7880), 348-352, 2021 | 214 | 2021 |
| PIK3CA in cancer: The past 30 years R Arafeh, Y Samuels Seminars in cancer biology 59, 36-49, 2019 | 152 | 2019 |
| Recurrent inactivating RASA2 mutations in melanoma R Arafeh, N Qutob, R Emmanuel, A Keren-Paz, J Madore, A Elkahloun, ... Nature genetics 47 (12), 1408-1410, 2015 | 123 | 2015 |
| Harnessing synthetic lethality to predict the response to cancer treatment NAture Communications, 2018 | 116 | 2018 |
| Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer SC Baca, DY Takeda, JH Seo, J Hwang, SY Ku, R Arafeh, T Arnoff, ... Nature communications 12 (1), 1979, 2021 | 88 | 2021 |
| miR-27a and miR-27a* contribute to metastatic properties of osteosarcoma cells Z Salah, R Arafeh, V Maximov, M Galasso, S Khawaled, S Abou-Sharieha, ... Oncotarget 6 (7), 4920, 2015 | 61 | 2015 |
| A genome‐wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS‐mutant melanoma A Nagler, DW Vredevoogd, M Alon, PF Cheng, S Trabish, S Kalaora, ... Pigment cell & melanoma research 33 (2), 334-344, 2020 | 29 | 2020 |
| Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells R Arafeh, K Flores, A Keren-Paz, G Maik-Rachline, N Gutkind, ... Scientific reports 7 (1), 16345, 2017 | 17 | 2017 |
| CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies JH Hwang, R Arafeh, JH Seo, SC Baca, M Ludwig, TE Arnoff, L Sawyer, ... Elife 11, e73223, 2022 | 10 | 2022 |
| RASA2 and NF1; two-negative regulators of Ras with complementary functions in melanoma R Arafeh, A Di Pizio, AG Elkahloun, O Dym, MY Niv, Y Samuels Oncogene 38 (13), 2432-2434, 2019 | 9 | 2019 |
| CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma M Alon, R Arafeh, JS Lee, S Madan, S Kalaora, A Nagler, T Abgarian, ... Oncotarget 9 (58), 31264, 2018 | 9 | 2018 |
| Systematic interrogation of tumor cell resistance to chimeric antigen receptor T-cell therapy in pancreatic cancer KR Hagel, R Arafeh, S Gang, TE Arnoff, RC Larson, JG Doench, ... Cancer research 83 (4), 613-625, 2023 | 6 | 2023 |
| MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters O Yakovian, J Sajman, R Arafeh, Y Neve-Oz, M Alon, Y Samuels, ... Cancer Research 81 (5), 1279-1292, 2021 | 2 | 2021 |
| Creb5 reprograms nuclear interactions to promote resistance to androgen receptor targeting therapies J Hwang, R Arafeh, JH Seo, SC Baca, M Ludwig, TE Arnoff, C Richter, ... bioRxiv, 2021.08. 18.456892, 2021 | 1 | 2021 |
| Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma M Alon, R Arafeh, JS Lee, S Madan, S Kalaora, A Nagler, T Abgarian, ... Oncotarget 10 (13), 1344, 2019 | 1 | 2019 |
| NRas activity is regulated by dynamic interactions with nanoscale signaling clusters at the plasma membrane O Yakovian, J Sajman, M Alon, R Arafeh, Y Samuels, E Sherman Iscience 25 (11), 2022 | | 2022 |
| Combination therapy for the treatment of cancer Y Samuels, R Arafeh, K Flores, R Seger, E Wainstein US Patent 11,471,504, 2022 | | 2022 |
| Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells (vol 7, 16345, 2017) R Arafeh, K Flores, A Keren-Paz, G Maik-Rachline, N Gutkind, ... SCIENTIFIC REPORTS 9, 2019 | | 2019 |
| Author Correction: Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells R Arafeh, K Flores, A Keren-Paz, G Maik-Rachline, N Gutkind, ... Scientific Reports 9, 2019 | | 2019 |
| A systematic and an unbiased genomic analysis to identify novel targets in melanoma R Arafeh PQDT-Global, 2018 | | 2018 |
